Tertomotide is under clinical development by GemVax & KAEL and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tertomotide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Tertomotide in Breast Cancer

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tertomotide overview

Tertomotide hydrochloride (Riavax) is a peptide vaccine. It is formulated as lyophilized powder for solution for intradermal route of administration. Riavax is indicated for the treatment of locally advanced or metastatic pancreatic cancer patients whose serum eotaxin level is higher than 81.02pg/mL. Tertomotide hydrochloride is indicated for emergency use in the treatment of coronavirus disease 2019 (COVID-19) associated cytokine release syndrome.
The vaccine candidate is under development for the treatment of Alzheimer's disease, benign prostatic hyperplasia, prostate cancer, hepatitis B, periodontitis and breast cancer. The vaccine candidate is administered through intradermal and subcutaneous route. The vaccine candidate targeting gonadotropin releasing hormone receptors (GnRHRs). It was also under development for the treatment of colorectal cancer, chronic lymphocytic leukemia (CLL), non-small cell lung cancer, allergic rhinitis, Coronavirus disease (COVID-19), multiple sclerosis, rheumatoid arthritis, sepsis, ischemia reperfusion injury, periodontitis, cancer cachexia, kidney disease, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, melanoma, metastatic adenocarcinoma of pancreas (global), progressive supranuclear palsy (PSP) and asthma.

GemVax & KAEL overview

GemVax & KAEL is a pharmaceutical company. It develops and manufactures anti-cancer immunotherapeutic and peptide drugs to treat cancer. The company’s lead product candidate GV1001, an immunotherapeutic peptide is used for the treatment of advanced or metastatic pancreatic cancer. GemVax & KAEL is also investigating the GV1001 drug against prostate cancer, benign prostate enlargement, Alzheimer’s disease and non-small cell lung carcinoma (NSCLC). The company also manufactures semiconductors and other equipment filters, pharmaceuticals, mobile solutions and fashion products. It distributes its products within the domestic market and to overseas markets. GemVax & KAEL is headquartered in Daejeon, South Korea.

For a complete picture of Tertomotide’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.